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	
Background: The survival of human immunodeficiency virus (HIV) -infected patients has 
increased significantly since the introduction of combination antiretroviral therapy, leading 
to the development of important long-term complications including cardiovascular and renal 
disease. Microalbuminuria, an indicator of early glomerular injury, and hypertension is 
associated with an increased risk of progressive renal deterioration, cardiovascular disease 
and mortality. There is a scarcity of data regarding prevalence of microalbuminuria and 
hypertension in HIV-infected individuals. Although causal blood pressure is linked to 
cardiovascular complications, ambulatory blood pressure and in particular nondipping 
pattern is more closely associated with hypertensive target organ damage and mortality in 
hypertensive individuals without HIV-infection. Furthermore, there are no data available 
with regard to ambulatory blood pressure in HIV-infected individuals.  
Aims of the thesis: To investigate the prevalence of microalbuminuria in HIV-infected 
individuals, compare the prevalence in Caucasians in the HIV-infected population with the 
general population, and identify possible predictors of microalbuminuria. 
To investigate the prevalence of hypertension in HIV-infected individuals, compare the 
prevalence in Caucasians in the HIV-infected population with the general population, and 
indentify possible predictors of hypertension. 
To describe ambulatory blood pressure in hypertensive, but untreated HIV-infected 
individuals, and compare the circadian blood pressure rhythm with that of HIV-uninfected 
controls and identify possible predictors of circadian blood pressure pattern. 
Methods: Patients were enrolled in an unselected manner from the outpatient clinic of the 
department of infectious diseases, Ullevål University Hospital, Oslo, Norway between 
March 2004 and November 2005 (n = 597). General data was obtained from the study 
questionnaire, local HIV database and patient record. When the database was closed in 
January 2007, 542 individuals had completed the study. 
Based on two or three urine samples, collected at separated clinical visits, microalbuminuria 
was defined according to albumin creatinine ratio between 2.5 and 30 mg/mmol. The 
nonhypertensive, nondiabetic HIV-positive cohort (n = 495) constituted the study sample 
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for paper I, and the Caucasian share was compared with a population-based 
nonhypertensive, nondiabetic control group (n = 2091). 
Blood pressure was measured under standardized circumstances in duplicate at three 
consecutive clinical visits. Hypertension was defined according to the guidelines of the 
European Society of Hypertension. The study sample was compared with an age-, sex- and 
body mass index matched population-based control group (n = 24968, paper II). 
Based on the casual blood pressure measurements, ambulatory blood pressure over 24h was 
carried out in 77 newly diagnosed untreated hypertensive HIV-positive individuals and 
compared with 76 HIV-uninfected untreated hypertensive controls (paper III). 
Results: The prevalence of microalbuminuria was 8.7% in the nonhypertensive, nondiabetic 
HIV-infected cohort, which is for the Caucasian fraction, depending on different age groups, 
2–5 times higher than in the general population. Combination antiretroviral treatment did 
not affect the prevalence of microalbuminuria. In multivariate analysis, systolic blood 
pressure (P < 0.0001), serum beta 2-microglobulin (P = 0.001) and duration of HIV 
infection (P = 0.019) were found to be independent predictors of microalbuminuria. 
The prevalence of hypertension among the Caucasian HIV-infected subjects was 36.5%, 
which was not significantly different from the general population. The mean diastolic blood 
pressure was significantly higher in both HIV-infected men and women (only for those with 
BMI < 25 kg/m
2
) compared to control subjects. The highest prevalence of hypertension in 
entire cohort was found in those who were treated by combination antiretroviral therapy for 
more than five years (44.4%). Multivariate analysis revealed age (P < 0.0001), gender (P = 
0.002), body mass index (P < 0.0001), cholesterol (P = 0.045), duration of combination 
antiretroviral therapy (P = 0.02) and microalbuminuria (P = 0.003) as independent 
predictors of hypertension. 
Hypertensive, HIV-infected subjects had more frequently an attenuated ambulatory blood 
pressure rhythm with a reduced nocturnal blood pressure fall than HIV-negative control 
subjects (60% vs. 33%, respectively; P = 0.001). Multiple logistic regression analysis with 
dipping pattern, i.e. normal nocturnal fall in blood pressure as dependent variable showed 
that HIV status, was an independent predictor of nondipping blood pressure (P = 0.002), 
while combination antiretroviral therapy had no predictive value. 
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Conclusions: Our findings indicate that inflammatory activity induced by HIV per se may 
be involved in the development of microalbuminuria, high blood pressure levels and 
attenuated blood pressure rhythm. Cardiovascular risk in the HIV-infected population seems 
to be influenced by a composite of the duration of both cART treatment and HIV infection. 
With respect to the increasing risk of developing cardiovascular, renal diseases and 
mortality, the high prevalence of microalbuminuria and attenuated blood pressure rhythm in 
HIV-infected individuals warrants special attention. 
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	
Out of an unpretentious afternoon ‘chatter on ward 112’ of the infectious diseases at Ullevål 
University Hospital in spring 2003 emerged what later would become the MAHO study. 
Nevertheless do politicians still speculate about what we are unnecessarily debating about… 
After introduction of combination antiretroviral therapy, the promising prospects for HIV-
infected individuals were disturbed by evidence of enhanced cardiovascular and although 
less striking even renal diseases. Metabolic adverse events by the antiretroviral therapy itself 
were primarily suspected, and even intrinsic long-term complications analogous to diabetic 
patients were postulated. 
The term ‘microalbuminuria’, a well-documented risk factor for cardiovascular and renal 
diseases was launched into a general afternoon discussion among infectious disease 
physician. In this premature phase, Olav Øktedalen supported the theory that elevated levels 
of microalbuminuria might be present in HIV infected individuals and motivated me to 
elaborate a study protocol. Finally, Oddbjørn Brubakk, the former chief of the department 
was confident to the idea and provided the necessary ‘backup’ to run this prospective cohort 
study at the outpatient clinic.   
First of all, I would like to thank the participants of the MAHO study who have been 
outstanding patient and generous in their collaboration. Their sense for responsibility was 
the most necessary perquisite to execute the study. Furthermore, the nurses of the outpatient 
clinic have constituted the major pillar of the study, not only to carry out the blood pressure 
measurements and logistic challenges but also to motivate the study participants. Thank you 
Astrid Moe Rudi, Kjersti Selnes, Lise Sørsvang, Jorun Almark, Linda Skeie and Heidi 
Bertheussen; you did a fantastic job! 
I am very grateful to my daily mentor and main supervisor, Olav Øktedalen who had to 
absorb my frustrations and impatience in the critical phases. His gentle advices and 
guidance throughout the study have been irreplaceable and without his faith the study would 
not have been possible. 
Without a shadow of a doubt I stand in immeasurable gratitude to professor Ingrid Os. Her 
scientific creativity, never ending enthusiasm and imminent professional and sympathetic 
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support in the progress of this thesis has been phenomenal and will be essential for the 
MAHO study in the near future. 
In this special moment, I could not forget the person who actually ‘shepherded’ me to the 
world of research – Prof. Ivar Eide, my first ‘boss’ at Ullevål definitely sparked off the 
unknown scientific curiosity in me. 
This study was carried out at the Department of Infectious Disease and I want to thank 
profoundly all my colleagues of the outpatient clinic for the inclusion of study participants 
and meticulous completion of the questionnaire. 
Furthermore, I want to express my appreciation to the following for their contribution to the 
MAHO study: 
• Professor Leiv Sandvik for his always-entertaining statistical and scientific support 
to the papers. 
• Sigrun Elden of the Department of Nephrology, for her professional assistance with 
ambulatory blood pressure measurement. 
• Aud Stenehjem for the valuable provision of the control group data and collaboration 
in paper III. 
• Professor Jostein Holmen for the kindly provision of the data from the population 
survey in the Health Study of Nord-Trøndelag County, Norway (paper I and II). 
• The department of clinical chemistry for the promptly analysis of the urine samples. 
• Professor Johan Bruun for the establishment of the HIV database.  
• Oslo University Hospital, Ullevål for the opportunity to work under perfect research 
conditions in this fantastic environment. 
In spite of everything, my sincere and deepest thoughts go to all of them who today do not 
benefit from the most basic scientific medical advances.
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ABP  ambulatory blood pressure 
ACE  angiotensin-converting enzyme 
ACR  albumin/creatinine ratio 
AIDS  acquired immunodeficiency syndrome 
ARA  angiotensin-receptor antagonist 
BMI  body mass index 
BP  blood pressure 
cART  combination antiretroviral therapy 
CVD  cardiovascular disease 
CKD  chronic kidney disease 
CRP  C-reactive protein 
DAD study Data Collection on Adverse events of Anti-HIV Drugs 
DBP  diastolic blood pressure 
ESRD  end-stage renal disease 
GFR  glomerular filtration rate 
HDL  high-density lipoprotein 
HIV  human immunodeficiency virus 
HIVAN HIV associated nephropathy 
HT  hypertension 
MA  microalbuminuria 
MDRD Modification of Diet in Renal Disease 
HUNT study Health Study of Nord-Trøndelag County, Norway 
NRTI  nucleoside reverse transcriptase inhibitor 
NNRTI non-nucleoside transcriptase inhibitor 
PI  protease inhibitor 
SBP  systolic blood pressure
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1.1 Human Immunodeficiency Virus Infection 
In 1981 the first cases of acquired immune deficiency syndrome (AIDS) were described.
1
 
Infection with HIV occurs by the transfer of blood, semen, vaginal fluid, pre-ejaculate or 
breast milk. The four major routes of transmission are unsafe sex, contaminated needles, 
breast milk, and transmission from an infected mother to her baby at birth (Vertical 
transmission). HIV has been found at low concentrations in the saliva, tears and urine of 
infected individuals, but there are no recorded cases of infection by these secretions and the 
potential risk of transmission is negligible. Furthermore, the infectiosity of HIV is strongly 
related to the viral load in the blood of the patients. There are two strains of HIV known to 
exist: HIV-1 and HIV-2. HIV-1 is the virus that was initially discovered; it is more virulent, 
relatively easily transmitted, and is the cause of the majority of HIV infections globally. 
HIV-2 is less transmittable and is largely confined to West Africa. Shortly after, the HIV 
was identified as the cause of AIDS, and preventive campaigns emerged all over the 
industrialised world in order to condition our sexual behaviour. Africa, the epicentre of the 
epidemic did not respond to it before the 90s, and even in recent years irresponsible political 
behaviour and unethical economic interests do still appear on the agenda. Despite an 
unprecedented global commitment, the number of people living with HIV is increasing and 
less than 1 of 4 who is in need of treatment does receive appropriate therapy, and this affects 
especially children. Today approximately 33 million individuals (Fig. 1) are infected and 
due to high viral load are many of them highly contagious, leading to a prevalence that have 
reached up to 25% among the population between 15-49 years in certain localities.
2
 In the 
countries most heavily affected, HIV has reduced life expectancy by more than 20 years, 
slowed economic growth, and deepened household poverty. In sub-Saharan Africa alone, 
the epidemic has orphaned nearly 12 million children aged less than 18 years. According to 
the United Nations Development Programme, HIV has inflicted the “single greatest reversal 
in human development” in modern history. Globally transmission modes remain 
predominantly heterosexual contact, sex work and vertical transmission during and shortly 
after pregnancy, while in the industrialised world men who have sex with men and 
intravenous drug abuse account for the majority of new cases of HIV infection. 
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Fig. 1 
 
 
 
 
Until 1987, when the first antiretroviral therapy trials were initiated, patients with HIV 
infection died after few years, predominantly by opportunistic infections. The mono-therapy 
with zidovudine, a nucleoside reverse transcriptase inhibitor (NRTI), and later duo-therapy 
was finally followed in 1996 by the combination of at least three different drugs, phrased 
‘highly active antiretroviral therapy’ (HAART) combining two NRTI’s with either a 
protease inhibitor (PI) or a non nucleoside transcriptase inhibitor (NNRTI). Recently two 
new groups, the fusion- and integrase inhibitors have been added to the repertoire to meet 
the increasing challenge of therapy resistance. Where available, these medications have led 
to eminent mortality reduction in HIV cohorts all over the world,
3
 reaching even mortality 
rates comparable to the general population.
4
 However, since there is no medication without 
side effect, combination antiretroviral therapy (cART) has shown to induce metabolic 
abnormalities, such as increased triglyceride and cholesterol levels, insulin resistance and 
lipodystrophy,
5
 in particular with PI. Consequently, HIV infection became a chronic, 
manageable and controllable disease. Other non-AIDS defined maladies, like malignancies, 
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cardiovascular, liver and renal diseases have gained increasing importance, as a result of the 
increased life expectancy, increased duration of HIV-infection per se and/or the inevitable 
adverse events by the antiretroviral therapy. 
1.1.1 Immunological implications 
HIV infection is characterized by the continuous loss of CD4+ T cells and an increase in 
viral load, leading to immunodeficiency, opportunistic infections, and death. The stage of 
infection can be determined by measuring the patient's CD4+ T cell count, and the viral load 
of HIV in the blood. 
HIV infection has basically four stages: incubation period, acute infection, latency stage and 
AIDS. The initial incubation period upon infection is asymptomatic and usually lasts 
between two and four weeks. The second stage is an acute infection, which lasts on average 
28 days and can include symptoms like fever, lymphadenopathy, pharyngitis, rash, myalgia, 
malaise, and mouth and oesophageal sores. The latency stage shows few or no symptoms 
and can last anywhere from two weeks to twenty years and beyond, before reaching AIDS, 
the fourth and final stage of HIV infection characterized by complicating opportunistic 
infections or tumors. 
HIV primarily infects vital cells in the human immune system such as helper T cells 
(specifically CD4+ T cells), macrophages, and dendritic cells. The main cell target is the 
CCR5+CD4+ T cell (Th 17+), predominantly found in the mucosal lymphoid tissues, such 
as the gastrointestinal tract, but direct infection of other organs, such as central nervous 
system, heart and kidneys have been reported. Additionally, HIV infection leads to low 
serum levels of CD4+ T cells through three main mechanisms in the lymph nodes and 
thymus: firstly, direct viral killing of infected cells; secondly, increased rates of apoptosis in 
infected cells; and thirdly, killing of infected CD4+ T cells by CD8 cytotoxic lymphocytes 
that recognize infected cells. When CD4+ T cell numbers decline below a critical level 
(<200/mm
3
), cell-mediated immunity is severely decreased, and the body becomes 
progressively more susceptible to opportunistic infections. Thus, in asymptomatic 
individuals with low viral load (<100,000 copies/ml), cART is initiated in the industrialized 
world at CD4 <350/mm
3
.
6
 CART increases the number of CD4 cells and suppresses viral 
load. The initial phase of 3-6 month after starting treatment is characterized by a rapid 
increase of CD4 cell count through release of memory cells trapped in the lymphoid system, 
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while in the second slower phase additional naïve cells from the thymus contribute to the 
reconstitution of the immune system. Recovery can be overwhelming, and lead to the 
immune reconstitution inflammatory syndrome (IRIS), an inflammatory response towards 
either an occult infection or paradoxical symptomatic relapse of a prior treated infection. 
The CD4 cell range reached by treated patients strongly depends on CD4 cell values at 
baseline, age, duration of HIV infection and viral suppression, and one-third will not reach a 
normal CD4 cell counts >500/mm
3
 after 5 years of treatment despite continuous viral 
suppression. 
1.1.2 Cardiovascular risk/disease in the era of cART 
Immediately after the introduction of combination antiretroviral therapy (cART), case 
reports of myocardial infarction in young patients infected with HIV sparked interests in the 
relationship between HIV infection and cardiovascular disease.
7
 The first to report an 
association between cART/PI exposure and myocardial infraction was based on the French 
hospital HIV database.
8
 The same study group confirmed later the increased risk of 
myocardial infarction in HIV-positive individuals compared to the general population 
(Fig.2).
9
 
FIG. 2. A, Myocardial infarction rates and corresponding adjusted RR. Bars indicate crude rates of AMI 
events per 1000 PY as determined by ICD coding. RR and associated P value are shown above the bars. RR 
was determined from Poisson regression analysis adjusting for age, gender, race, hypertension, diabetes, and 
dyslipidemia. Associated 95% CIs for RR shown are 1.51–2.02. B, Myocardial infarction rates by age group. 
Light line indicates patients diagnosed with HIV disease. Dark line indicates patients not diagnosed with HIV 
disease. Data shown include both genders. Rates represent number of events per 1000 PY as determined by 
ICD coding. 
 
Reproduced with permission from The Journal of Clinical Endocrinology & Metabolism; VA.Triant et al. J 
Clin Endocrinol Metab 2007;92:2506-2512 
After AIDS defining events, hepatitis B or C induced liver disease and non HIV-related 
malignancies, cardiovascular disease (CVD) has become the fourth cause of death in well 
treated HIV infected cohorts.
10
 Patients with HIV infection share cardiovascular risk factors 
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with the general population,
11
 and some of them can be induced by the different components 
of cART.
12
 Increased total cholesterol, reduced high-density lipoprotein (HDL) -cholesterol, 
increased triglyceride levels and a diagnosis of hypertension (HT) and diabetes are all 
associated with cART. Especially PI-containing cART induces dyslipidemia, insulin 
resistance and altered fat distribution or lipodystrophy,
5,13
 while the mitochondrial 
dysfunction caused by the thymidine analogues stavudine and zidovudine within the NRTI’s 
results in insulin resistance and increased incidence of diabetes.
14,15
 However, besides the 
treatment-associated metabolic side effects, prolonged cART exposure itself was identified 
as an independent risk factor, with a 26% relative increase in the rate of myocardial 
infarction per year during the first four to six years of use.
16
 The researchers conducting that 
study described later that increased exposure to PI’s
11
 and recent use of certain NRTI’s
17
 
were associated with an increased risk of myocardial infarction, while no such evidence was 
found for NNRTI’s. Interestingly, PI’s have in small studies been associated with impaired 
vasodilatation,
18
 vasomotor dysfunction
19
 and increased aortic stiffness.
20
 Thus, endothelial 
dysfunction has emerged as a putative mechanism of the enhanced arteriosclerosis in HIV-
infected individuals. 
The traditional cardiovascular risk factors, such as hypercholesterolemia, elevated BP and 
insulin resistance nowadays are seen as factors associated with increased inflammation. 
Moreover, several inflammatory molecules are expressed in the early stages of 
arteriosclerosis suggesting that it is mainly an inflammatory process. Therefore, it is not 
surprising to propose that chronic HIV infection itself, low-grade inflammation and 
immunological status are also involved in the development of CVD.
21
 Unfavourable lipid 
changes can be induced by high HIV replication and lower CD4 count. In addition, dilated 
cardiomyopathy has frequently been found in even naïve HIV-positive cohorts
22,23
, and up 
to 57% of asymptomatic individuals have ECG-abnormalities.
24
 Although not in abundance, 
HIV infects directly the myocytes,
25
 and persists within macrophages between myocardial 
cells even after the effective initiation of cART. These reservoir cells may exhibit HIV on 
their surfaces and generate progressive tissue damage through virus-induced chronic release 
of cytotoxic cytokines.
26
 
Overall, most likely both cART and HIV contribute to the pathogenesis of CVD by 
mechanisms that may affect lipids, insulin sensitivity and the structural and functional 
vasculature. These mechanisms are not well understood and conflicting results are often 
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based on short-term studies, while the development of CVD is undoubtedly a long-term 
consequence of multifactorial aetiology. 
1.1.3 Renal diseases in HIV-infected individuals 
Chronic kidney disease (CKD) in its different stages is in the general population 
independently related to higher risk of death, development of cardiovascular diseases, and 
higher hospitalization rates.
27
 HIV-associated nephropathy (HIVAN), first described in 
1984,
28
 the most common or "classical", type of HIV-associated renal diseases is 
characterized as a collapsing focal segmental glomerulosclerosis. HIVAN occurs almost 
exclusively in black individuals with an advanced stage of the HIV infection, i.e. low CD4 
cell count <200 and high viremia presents with nephrotic syndrome and rapid progressive 
renal failure. In a large CKD cohort, HIV-infected African American individuals had a 
adjusted incidence of end-stage renal disease (ESRD) approximately 6.3 times greater than 
Caucasians and a rate similar to African American individuals with diabetes.
29
 However, 
with prolonged survival and aging of the HIV-infected population in the industrialized 
world with access to cART, the spectrum of kidney disease in individuals with HIV also 
reflects the growing burden of co-morbid diabetes and HT,
30,31
 and kidney function has been 
estimated to be abnormal in up to 30% of HIV-infected individuals.
32
 Furthermore, different 
HIV-related histological forms, beside HIVAN, such as immune complex 
glomerulonephritides and thrombotic microangiopathy have gained attention, and are also 
present in non-black ethnicities. Moreover, several drugs used in the treatment of HIV, 
including antiretrovirals, antibacterials used to treat opportunistic infections and 
medications used for associated co-morbid conditions have nephrotoxic potential.
33
 Among 
antiretroviral agents, especially indinavir and tenofovir have caused tubular disorders and 
interstitial nephritis,
34
 and found to be associated with increased risk of chronic renal 
failure.
35
 Regardless of the underlying histology, renal diseases in HIV-positive patients are 
associated with an increased risk of death.
36
 
Although the increasing prevalence of chronic kidney disease in HIV-infected cohorts can 
be largely attributed to traditional risk factors,
37
 they might in addition be caused by direct 
HIV infection of the renal cells, with resulting renal damage of both glomerular and tubular 
cells through the viral gene products.
38
 Other chronic inflammatory pathways induced by 
HIV infection also seem to be plausible but further prospective investigations have to be 
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undertaken. Microalbuminuria (MA), an early marker of progressive renal diseases in the 
general population, is associated with inflammatory markers in patients with malignancies,
39
 
chronic inflammatory diseases,
40
 as well as diabetes.
41
 Whether MA is associated to any 
inflammatory process in HIV-infected individuals has previously never been observed. 
Nevertheless, MA was found to be a predictor of renal diseases in a selected South African 
HIV cohort.
42
 Despite that, there is agreement that cART
43
 in combination with angiotensin-
converting enzyme (ACE) inhibitors
44
 is the indispensable therapy of advanced HIV related 
renal diseases and might even be prevented.
45
 
1.2 Inflammation and endothelial dysfunction 
Recent research indicates that not only traditional risk factors such as lipid abnormalities, 
insulin resistance and high blood pressure, but also inflammatory processes are involved in 
the pathogenesis (Fig. 3) and progression of cardiovascular and renal diseases.
46,47
 
Proinflammatory cytokines can cause endothelial injury and dysfunction that leads to a less 
negatively charged glomerular capillary wall and subsequently to MA. In diabetic patients 
with MA, biomarkers of endothelial dysfunction and inflammation may predict the 
progression of nephropathy.
48
 In addition, systemic inflammations may enhance 
atherogenesis, e.g. the increased incidence of CVD in patients with systemic lupus 
erythematosus,
49
 rheumatoid arthritis, inflammatory bowel disease, HIV
7
 and even 
periodontitis.
50
 Inflammation and endothelial dysfunction might be important factors for the 
increasing incidence of CVD among HIV-infected patients.
51
 Carotid intima media 
thickness, a validated marker of preclinical atherosclerosis, has been found to be increased 
in HIV-infected compared to uninfected individuals.
52
 In that study an inflammatory 
mechanism associated to cytomegalovirus specific T-cell responses was identified. Maggi et 
al. found an astonishing similarity in endothelial plaques of the carotid arteries between 
patients with arthritis and HIV infection, suggesting a similar inflammatory component in 
HIV-infected individuals.
53
 Furthermore, systemic inflammation can induce endothelial 
dysfunction, through a reduction of the vasodilator nitric oxide (NO), a mechanism also 
attributed to adverse events by certain protease inhibitors even in healthy volunteers.
19,54
 In 
contrast, HIV causes excessive production of NO, which enhances the production of 
peroxynitrite
55
 another contributor to endothelial dysfunction.
55
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Fig. 3 The role of inflammation in the pathogenesis of atherosclerosis. 1) Inflammation of the endothelium 
stimulates the production of adhesion molecules (E-Selectin, ICAM-1, PECAM-1). 2) Chemotactic cytokines 
(MCP-1 and M-CSF) lead the migration of monocytes and macrophages. 3) Leukocytes turn into macrophages 
and activate the receptor for the oxidized LDL cholesterol. 4) TNF and TNF are produced by lymphocytes. 
Metalloproteases are responsible for local necrosis. 5) IL-6 induces the production of tissue factor (TF) and 
plasminogen activator inhibitor-1 (PAI-1), that activate the coagulation and inhibit the fibrolysis. 
 
Reproduced with permission from Claudio Ferri; Maggi P et al. AIDS Reviews. 2006 Oct-Dec;8(4):204-9. 
Several inflammatory markers have been identified as a putative cause for CVD in the 
general population, and some of them have also been found to be increased in HIV-infected 
individuals.
51
 C-reactive protein (CRP), a marker of low-grade inflammation has been 
associated with CVD, hypertension and end-stage renal disease in the general 
population,
56,57
 but this could until now not be confirmed in HIV-infected individuals. 
Nevertheless, CRP positively increases the association between MA and BP (Figure 4).
58
 
Although the level of CRP has been shown to be relatively low in various studies for a 
populations with ongoing HIV infection, CRP is associated with inverse CD4 cell count, 
progression to AIDS and mortality.
59
 Thus, it has even been proposed in follow-up of HIV-
infected patients in regions where antiretroviral therapies are becoming available but where 
frequent monitoring with viral loads and CD4 counts is still cost-prohibitive.
60
 Furthermore, 
increased levels of marker of endothelial activation and proinflammatory cytokines, have  
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Fig. 4 Graphical depiction of the interaction between CRP and mean arterial blood pressure on the estimated 
prevalence of microalbuminuria (multivariate design-based logistic regression analyses). Thus, this figure 
indicates the regression lines of a never-smoking male with an average age (48.4 years), BMI (25.9 kg/m
2
), 
waist circumference (93 cm), glucose (4.7 mmol/L), cholesterol (5.6 mmol/L) and not using antihypertensive 
or lipid-lowering drugs. Predicted prevalence of microalbuminuria (%) according to levels of C-reactive 
protein and mean arterial blood pressure. 
 
Reproduced with permission from Dick de Zeeuw; Stuveling, E. M. et al. Hypertension 2004;43:791-796 
been associated with progression and severity of HIV-infection.
21,61
 HIV in synergy with 
tumour necrosis factor-, can bind to the endothelial cells, causing proliferation and through 
adhesion molecules, migration of monocytes into endothelium responsible for inflammatory 
cascade.
62
 The SMART study, demonstrated that an increased risk of myocardial infarction 
was associated with IL-6 and D-dimer, in the CD4 guided treatment interruption arm 
compared with matched patients receiving continuous cART. Although, it might be 
expected that cART attenuates inflammation by reducing viral load, it is plausible that HIV 
per se, as well as the immune reconstitution process, promote premature endothelial lesions 
by a massive activation of inflammation molecules and cells.
63
 
1.3 Microalbuminuria 
The term ‘microalbuminuria’ first appeared in 1981, when Viberti et al. observed the 
presence of proteinuria below the detection limit of standard dipstick in diabetic patients and 
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it’s predictive value for nephropathy.
64
 MA occurs when the kidney leaks small amounts of 
albumin into the urine, secondary to glomerular endothelial injury, i.e. increased 
permeability for albumin in the renal glomerular barrier. The increased permeability may be 
a consequence of the loss of negative charged surface of the glomerular capillary wall that 
normally repels the negative charged proteins, intraglomerular hypertension and podocyte 
injuries, caused by oxidative radicals, proinflammatory cytokines and endothelial 
dysfunction. 
Only small amounts of albumin are normally present in the urine, because it is retained in 
the bloodstream or reabsorbed in the tubuli of the kidneys. MA diagnosed from a 24-hour 
urine collection (20 to 200 g/min), is a cumbersome and often unreliable method, while 
measurements of albumin concentration (MA range 30 to 300 mg/L) in spot urine is more 
commonly used. As there is a wide day-to-day variation, and MA is influenced by activity, 
fever and nutrition, MA should be measured on at least two occasions weeks to months 
apart. To compensate for variations in albumin urine concentration in a spot-urine, albumin 
is compared against the concentration of creatinine. This is termed the albumin/creatinine 
ratio (ACR) and MA is defined as ACR 2.8 mg/mmol (female) or 2.0 mg/mmol (male) 
and below 30 mg/mmol for both sexes.
65
 These cut-offs are arbitrary, and cardiovascular 
and renal risk is increasing even using lower cut-off levels.
66,67
 
MA is observed in a number of clinical conditions, i.e. diabetes, hypertension, malignant 
diseases,
39
 symptomatic urinary tract infections
68
 and other inflammations,
69
 intake of 
protein rich food,
70
 exercise
71
 and longstanding upright position
72
. Notwithstanding, MA is 
an important:  
• Indicator of subclinical cardiovascular disease in the general population73,74 
• Predictor of mortality in the general population75,76 
• Marker of vascular endothelial dysfunction77 
• Prognostic marker for progressive kidney disease 
o In the general population78 
o In diabetes mellitus79 
o In hypertension80 
MA has therefore gained increasing recognition as a simple marker of an atherogenic 
propensity. 
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1.3.1 Microalbuminuria in the HIV-infected population 
The association between HIV infection and MA has previously been observed in selected 
study populations in the pre-cART era, with a prevalence ranging from 19% to 34%.
81-83
 
Apart from a recently published study, from which a fivefold higher rate of MA was 
reported in HIV infected patients than in a matched, but not population-based, control 
group,
84
 most studies have investigated proteinuria related to HIV associated 
nephropathy.
42,85,86
 Prospective studies have shown that individuals with proteinuria after 
the initiation of cART, have higher mortality, higher risk of hospitalisation and increased 
risk of cardiovascular disease compared to those without proteinuria.
36,87
 In a South African 
study of cART naïve individuals, MA was an early marker of biopsy confirmed HIVAN.
42
 
Moreover, in a recent autopsy study from New York, where chronic kidney disease was 
present in the majority it was presumed that several individuals could have identified by 
pre-mortem MA testing.
88
 Today, the Infectious Diseases Society of America (IDSA) 
guidelines on the management and detection of chronic kidney disease in HIV recommend 
use of a conventional urine dipstick, with a threshold for detection of renal disease at 1+ 
proteinuria.
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1.4 Hypertension 
Persistent HT is the most important risk factor for strokes, heart attacks, heart failure and 
arterial aneurysm, and is a leading cause of chronic renal failure.
89,90
 The World Health 
Organization attributes HT as the leading cause of cardiovascular mortality, and even 
moderate elevation of arterial blood pressure leads to shortened life expectancy. Beginning 
already at 115/75 mmHg, CVD risk doubles approximately for each increment of 20/10 
mmHg. The hypertensive target organ damages can primarily be detected in the retina, heart 
and kidneys. It is estimated that 50% of the hypertensive population worldwide is unaware 
of their condition, and of those treated, less than half have their blood pressure controlled to 
a level of <140/90 mm Hg – the threshold for HT.
91
 
Even though age remains the most important risk factor, other variables like sedentary 
lifestyle, obesity, high alcohol intake and increased salt sensitivity have been identified to be 
associated with increased BP. The pathogenesis of essential HT is a complex, and with no 
single cause, but rather an interaction between genes, environmental factors, and activation 
of pressor systems, e.g. autonomic nervous system or renin-angiotensin-aldosteron system 
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and local contributor to functional alteration in the vasculature eventually leading to 
structural changes and endothelial dysfunction.
92
 
Antihypertensive drugs were first developed in the 60s. Despite the development of an 
armamentarium of medications, the magnitude of BP reduction is more important predictor 
for cardiovascular benefit than the choice of drug. Unfortunately, even if generic products 
are available for less than one cent per person per day, the reality is that most people, who 
need antihypertensive treatment, receive no treatment whatsoever. 
1.4.1 Hypertension in the HIV-infected population 
Before cART, HT has been a rather neglected research field among HIV cohorts. With 
increased life expectancy and occurrence of premature CVD in HIV-infected individuals, 
hypertension has gained interest. However, the prevalence of HT in different selected HIV-
infected cohorts ranges from 8% to 34%.
93-100
 This may reflect both differences in age, sex, 
race, immunological status and cART medication regimes and treatment duration in the 
cohorts. Only a few studies have investigated the prevalence of HT
93,94,96,99,100
 together with 
BP levels
93,96,101
 in HIV-infected populations compared with HIV-negative controls and 
these have shown diverging results. As in the general population, HT is strongly influenced 
by risk factors such as age, male gender, BMI, cholesterol and probably kidney diseases in 
HIV-infected individuals. An increase in BP has been found in HIV-infected patients during 
cART.
93,94,98,100,102-105
 However, most studies, including the The Data Collection on Adverse 
events of Anti-HIV Drugs (DAD) study, do attribute this not to cART therapy or one 
particular agent,
100,102,103
 but rather to the metabolic side effects of cART.
94,98,104,105
 Another 
interesting observation has been made by Crane et al. They found increased SBP or HT not 
previously recognized in HIV-infected individuals with CD4 cell count below 200/mm
3
 at 
treatment start, after a mean cART exposure of 13.5 months compared to those with higher 
CD4 cell count.
104
 To complete the inconsistency in findings, even reduced BP has been 
observed, mainly when selected cART naïve patients (e.g. young age, unadjusted for BMI 
or small samples) were compared with HIV-negative controls.
93,96,100,101
 
1.5 Ambulatory blood pressure 
Initially reserved for research purposes, ambulatory blood pressure (ABP) monitoring has 
gradually entered standard medical practice and has now become a widely used clinical tool, 
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both for diagnostic purposes and for assessment of treatment efficacy. Indications for use of 
ambulatory blood pressure monitoring include white-coat hypertension, borderline 
hypertension, and resistant hypertension. Twenty-four hour daytime or nighttime average 
BP values correlate with subclinical organ damage more closely, and are more predictive for 
cardiovascular risk than office values.
106,107
 A small study, has even suggested that elevated 
ABP is more strongly correlated with progression to ESRD than casual BP.
108
 
Ambulatory BP values are usually lower than the corresponding office values, as a 
consequence of the missing white-coat effect. Thus, the 24h BP should be lower than 
125/80 mmHg, while daytime BP should be below 130-135/85 mmHg, more closely 
corresponding to casual BP values of 140/90 mmHg.
109
 The predictive consequences of 
white coat hypertension might be linked to an increased risk of developing HT and 
strokes.
110,111
 Masked hypertension, i.e. normal office BP but elevated ABP, has emerged as 
an independent predictor of cardiovascular morbidity.
112
 ABP varies between day- and 
night-time (Fig.5). 
Fig. 5 Examples of ambulatory blood pressure graph in normotensive (upper-left), nocturnal hypertensive 
(upper-right), hypertensive with nocturnal dip (lower-left) and hypertensive without nocturnal dip (lower-
right) individual. 
 
Reproduced with permission from BMJ; O'Brien, E. et al. BMJ 2001;322:1110-1114 
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The average nocturnal fall in BP is approximately 15% from daytime values in both normo- 
and hypertensive individulals.
113
 Patients have been categorized into dippers and nondippers 
according to the nocturnal SBP fall compared daytime SBP of greater or less than 10%, 
respectively.
109
 Nondippers have the highest risk of cardiovascular complications.
114
 The 
blunted fall in BP is associated with left ventricular hypertrophy,
115-117
 increased albumin 
excretion,
115,118
 and mortality.
119-121
 The underlying mechanisms are unknown, but intrinsic 
renal defects may contribute.
122
 Nevertheless, a positive association between markers of 
inflammation (i.e. C-reactive protein and tumor necrosis factor) and ABP variability has 
been described for healthy, normotensive individuals.
123
 Others have observed that the 
nondipping BP pattern is related to inflammatory markers and endothelial dysfunction.
124
 
However, whether reversal of nondipping is possible or beneficial is yet not clarified. No 
former published investigations of ABP monitoring in HIV-infected individuals are 
available.
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Given this background, there is clearly a need for more data with regard to 
microalbuminuria, hypertension and ambulatory blood pressure in HIV-infected individuals. 
Thus, the specific objectives of the study were as follows: 
1 Identify the prevalence of microalbuminuria in a population-based, nonhypertensive 
and nondiabetic HIV-positive cohort, compare it to the general population and detect 
possible independent predictors. 
2 Identify the prevalence of hypertension in an entire urban HIV-cohort, compare it to 
the general population and detect possible independent predictors. 
3 To analyse the ambulatory blood pressure pattern in untreated hypertensive HIV-
positive individuals and compare it to an untreated hypertensive HIV-negative control 
group.
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3.1 Study sample 
The individuals included in the MAHO study cohort were recruited from the outpatient 
clinic of the Department of Infectious Diseases, Ullevål University Hospital, the main HIV 
clinic in Oslo. In the hospital server a HIV database was early established in the 90’ and 
record meticulously general characteristics, blood sample results and antiretroviral therapy 
regimes. All HIV-infected patients attending the clinic between March 2004 and November 
2005 were invited to participate in the study, and 597, all aged >20 years were enrolled in 
the MAHO  
Table 1 
Demographic and clinical data of the 542 individuals who completed the MAHO-study. 
Characteristics or laboratory value All 
n = 542 
Men 
n = 392 
Women 
n = 150 
Age groups, years 
< 30 
30–39 
40–49 
> 50 
 
60 (11.1%) 
170 (31.4%) 
179 (33.0%) 
133 (24.5%) 
 
24 (6.1%) 
114 (29.1%) 
131 (33.4%) 
123 (31.4%) 
 
36 (24.0%) 
56 (37.3%) 
48 (32.0%) 
10 (6.7%) 
Ethnicity 
White 
Black 
Asian 
 
382 (70.5%) 
125 (23.1%) 
35 (6.5%) 
 
322 (82.1%) 
54 (13.8%) 
16 (4.1%) 
 
60 (40.0%) 
71 (47.3%) 
19 (12.7%) 
Smokers 227 (41.9%) 177 (45.2%) 50 (33.3%) 
Cholesterol (mmol/L) 5.1 ± 1.1 5.1 ± 1.2 5.0 ± 1.1 
BMI (kg/m
2
) 24.1 ± 3.6 24.1 ± 3.3 24.0 ± 4.4 
SBP mmHg 130.2 ± 17.8 134.2 ± 17.0 119.8 ± 15.5 
DBP mmHg 81.0 ± 10.7 82.7 ± 10.7 76.3 ± 9.3 
HT (diagnosed before inclusion) 26 (4.8%) 25 (6.4%) 1 (0.7%) 
Hepatitis C positive 50 (9.2%) 31 (7.9%) 19 (12.7%) 
Duration since HIV test (years) 7.4 ± 5.9 7.5 ± 6.0 7.1 ± 5.9 
cART 
Naïve throughout the study 
Naïve at study inclusion 
< 2 years 
2–5 years 
> 5 years 
 
158 (29.2%) 
25 (4.6%) 
169 (31.2%) 
100 (18.5%) 
90 (16.6%) 
 
117 (29.8%) 
19 (4.8%) 
121 (30.9%) 
67 (17.1%) 
68 (17.3%) 
 
41 (27.3%) 
6 (4.0%) 
48 (32.0%) 
33 (22.0%) 
22 (14.7%) 
HIV RNA (copies/mL) 200 (0–31,000) 200 (0–35,000) 65 (0–19,000) 
CD4 (10
9
 cells/L) 0.38 (0.25–0.56) 0.38 (0.26–0.58) 0.38 (0.22–0.53) 
Creatinine (μmol/L) 70.8 ± 15.1 75.3 ± 13.2 59.1 ± 13.6 
Microalbuminuria 51 (9.4%) 40 (10.2%) 11 (7.3%) 
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study. No exclusion criteria were used, although inability to understand and sign the written 
information constituted a limitation to participate. Based on estimates from the Norwegian 
Surveillance System of Communicable Diseases, these patients constitute about 75% of the 
entire HIV-positive population in Oslo. Thus, they can be considered an unselected 
population of HIV-infected individuals from the whole city. Subjects were followed for up 
to 34 months, and 542 completed study criteria of three clinical visits when the database 
was closed in January 2007 (Table 1). 
3.1.1 Paper I 
From the 597 patients enrolled in the MAHO study, 55 patients were excluded because of 
dropout after the initial visit (n = 26), i.e. impossibility to establish contact, death (n = 12), 
moving abroad or to other clinics in Norway (n = 11) or unwillingness to continue the study 
after inclusion (n = 6), leaving 542 patients that completed the study. In addition, patients 
with previously diagnosed diabetes mellitus (n = 14), HT (n = 25), macroalbuminuria (n = 
5) or insufficient number of urine samples (n = 3) were excluded, remaining 495 individuals 
to be analysed. For the comparison with the control group, only Caucasians (n = 348) were 
included. 
3.1.2 Paper II 
All 542 individuals that completed the MAHO-study were analysed. For the comparison 
with the control group, only Caucasians (n = 236) were included. 
3.1.3 Paper III 
All individuals (n=147), categorized in the MAHO-study as hypertensive, based on the 
casual BP, and did not receive antihypertensive treatment were invited to undergo an 
ambulatory blood pressure monitoring. Of these invitees, 70 had either commenced 
antihypertensive treatment in the interim period or did not reply to the invitation; the 
remainder (n = 77) were eligible for inclusion in the study. 
3.2 Ethics 
All patients were given oral and written information by an infectious disease physician 
about the purpose of the study at the clinical consultation. Written consent to participate was 
given at the same session (Appendix, Pasientinformsjon). Additional written information 
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was given to those invited to the ambulatory blood pressure monitoring. Patients were 
recorded unidentified in the database with the identical code from the HIV database. The 
protocol of the MAHO-study was approved by the Regional Committee for Medical 
Research and the Norwegian Data Inspectorate. The study has been conducted in 
accordance with the World Medical Association Declaration of Helsinki. 
3.3 Control groups 
3.3.1 Paper I/II 
For both papers the large population-based second Nord-Trøndelag Health Study (HUNT-
2), 1995-1997, Norway (n=66140) served as comparative data. The HUNT-2 study covered 
the entire country’s population and is one of the most reliable health studies ever performed. 
All residents of Nord-Trøndelag County (n=92702), aged 20 years and older were invited to 
the health survey. An invitation letter was sent by mail attached to a questionnaire that had 
to be completed and returned at the attendance to the screening site, where a second was 
handed out. A wide range of topics, like previous diseases, personal environment, habits and 
family medical history was addressed.  In total 66.7% of the invited men and 75.5% of the 
invited women participated.
125
 
Five per cent of a randomly selected sample of the total population (n=2091), who did not 
answer 'yes' to one or both of the questions: 'Do you have diabetes?' and 'Do you take 
antihypertensive medication now?’ constituted the MA control group (paper I). 
In contrast, the control group for paper II was based on the entire HUNT-2 study population. 
3.3.2 Paper III 
The control group (n=76) consisted of untreated and newly diagnosed hypertensive subjects 
referred to the outpatient HT clinic at Ullevål University Hospital for ABP measurement. 
They had entered a study on the reproducibility and characteristics of ABP in a hypertensive 
population.
126
 To be eligible for that study, DBP measured at the HT clinic using a mercury 
sphygmomanometer had to be between 95 and 105 mmHg after 5 minutes rest in a sitting 
position and on two different occasions weeks apart.
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4.1 Study design 
The MAHO study was an unselected population-based, prospective, epidemiological cohort 
screening study of MA and blood pressure. 
4.1.1 Data collection 
General data was electronically extracted from the local HIV database to SPSS
®
. The basic 
questionnaire (Appendix; Spørreskjema) with information about race, smoking habits, drug 
abuse, malignancies, hepatitis C, diabetes, use of antihypertensive drugs and/or NSAID was 
entered into a epinfo
®
 database based on the hospital server. Data were taken from the date 
nearest to the inclusion in the study. Further information, i.e. date of visit, BP data, height 
and weight was copied from the backside of that questionnaire. Urinary albumin and 
creatinine, glycosylated hemoglobin HbA1c, cholesterol and high-density lipoprotein were 
manually copied from the data patient record. Finally, data from the HIV database, 
questionnaire and patients record were joint for further statistical analysis in a SPSS
® 
database. 
4.1.1.1 Microalbuminuria screening 
A urine sample was collected at each research visit, i.e. at the same time as BP 
measurements, for determination of the ACR, a measure for the urinary excretion rate of 
albumin.
127
 At the first visit the patient was asked to deliver a urine sample ‘straight away’. 
An additional urine container was handed out, in order to collect a morning midstream 
sample at the next visit. Patients, who underwent an antibiotic treatment for urinary tract 
infection or had ongoing urinary tract infection symptoms, where asked to deliver a urine 
sample at the next visit. Urine samples were sent and analysed promptly at the Department 
of Clinical Chemistry, Ullevål University Hospital. 
4.1.1.2 Blood pressure screening 
Highly trained physicians undertook three clinical visits, days to months apart. After the 
clinician consultation, BP was measured using a validated semiautomatic oscillometric 
device (Omron M4, Matsusaka Co. Ltd., Matsusaka, Japan). Cuff size was adjusted 
according to the arm circumference. Well-trained nurses performed two consecutive BP 
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measurements 2 min apart using an appropriate cuff size after the patient had rested in a 
relaxed, sitting position for 5 min in a quiet room. BP together with date was registered on 
the backside of the questionnaire. In addition, height and weight were measured at the first 
clinical visit. The BP in the control group of the first and second paper was measured with a 
validated semiautomatic device (Dynamap 845XT, Créteil, France).
125
 
4.1.1.3 Ambulatory blood pressure measurement 
Based on the casual BP measurements, untreated, hypertensive individuals were invited by 
letter to participate in an ABP monitoring. General information about the purpose of the 
investigation was enclosed to the letter (Appendix; MAHO – Pasientinformasjon – 24 t 
Blodtrykksregistrering). Furthermore, at attendance a basic questionnaire (Appendix; 
Dagbok) was handed out. This included information about the sleeping habits and 
experiences of discomfort during the ABP monitoring. 
ABP monitoring was performed using an oscillometric device (model 090207; SpaceLabs 
Medical Inc., Redmond, WA, USA). The 24-h BP measurements always began on a 
working day between 8:00 and 10:00. BP was measured at 20-min intervals during the day 
(07:00–22.00) and at 30-min intervals during the night (22.00–07.00). Cuff size was 
selected according to measured arm circumference, and the nondominant arm was always 
used. Furthermore, the patients were instructed to report any unexpected or unusual events 
during the registration period and whether sleep was markedly interrupted. The patients 
were instructed to keep their arm still during BP measurements to ensure good quality 
recordings. While in the control group ABP monitoring was performed using an 
auscultatory device; Tycos Quiet Trak (Welch/Tycos Instruments Inc., Skaneateles Falls, 
NY, USA) in the same outpatient clinic, definitions of HT were identically. 
4.1.1.4 HIV database 
Professor Johan Bruun established the HIV database in the 90s. It has been used for research 
purposes and for several scientific articles in highly esteemed and peer-reviewed 
journals
128,129
 and has been adequately evaluated. Age, sex, date of the patient’s first HIV-
positive test, transmission mode, CD4, HIV RNA, serum beta 2-microglobulin, serum 
creatinine, starting date of cART, hepatitis B status and death date were obtained from the 
local HIV database, updated continuously from the patients records.
130
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4.1.1.5 Questionnaire 
A basic questionnaire (Appendix; Spørreskjema) was completed in presence of a physician 
during the clinical consultation, comprising Yes/No questions of race, smoking habits, drug 
abuse, malignancies, hepatitis C, diabetes, hypertension and NSAID use. The questionnaire 
was primarily designed to evaluate possible causes of MA and has not been evaluated. 
4.1.1.6 Definitions 
MA was defined according to the ACR. Based on at least two urine samples, patients were 
categorized as having normoalbuminuria (< 2.5 mg/mmol), microalbuminuria (2.5–30 
mg/mmol) or macroalbuminuria (> 30 mg/mmol). The same criterion for the definition of 
microalbuminuria was used in Paper I for the HUNT-2 study control group.
131
 
Glomerular filtration rate (GFR), a measure of kidney function, was calculated based on the 
Modification of Diet in Renal Diseases (MDRD) equation, i.e. eGFR (ml/min) = 32788  
serum Creatinine (μmol/L)-1.154  Age-0.203  [1.21 if black]  [0.742 if Female], which takes 
into account serum creatinine, age, sex and race.
132
 
For statistical analyses, the mean of all three BP measurements taken in duplicate was 
calculated. HT was defined, according to guidelines by the European Society of 
Hypertension as systolic BP (SBP)  140 and/or diastolic BP (DBP)  90 mmHg, or 
reported diagnosis of HT with use of antihypertensive medications. Isolated systolic HT was 
defined as SBP  140 mmHg and DBP < 90 mmHg, isolated diastolic HT as SBP < 140 
mmHg and DBP  90 mmHg and combined systolic and diastolic HT as SBP  140 mmHg 
and DBP  90 mmHg.
109
 BP in the control group Paper II (HUNT-2) was taken once in 
triplicate using the mean of the two last readings for statistical analyses. 
Ambulatory blood pressure daytime and nighttime were defined as 07:00-22:00 and 22:00-
7:00, respectively. Nocturnal fall was defined as the percentage decrease in average SBP 
and DBP at night relative to daytime values. The patients were classified, according to the 
European guidelines
133
 as dippers or nondippers based on a nocturnal reduction in SBP of 
more or less than 10%, respectively. 
Duration of HIV was calculated from the date of the first positive HIV test to the date of the 
first clinical visit. Duration of cART treatment was calculated from the cART starting date 
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to the date of the first clinical visit. CART was defined as a combination of at least three 
different drugs including NRTI’s and at least one PI or NNRTI. 
4.1.2 Laboratory analyses 
Most of the study participants had their routine blood samples drawn between 8 and 11 a.m. 
after an overnight fasting. Urine albumin and creatinine were measured using an 
immunoturbimetric method (antihuman serum albumin antibody from Roche, Basel, 
Switzerland) and an enzymatic method (Roche), respectively. HIV RNA in EDTA plasma 
was quantified using polymerase chain reaction amplification with a COBAS Amplicor 
HIV-1 Monitor Test (Roche Diagnostics, Branchburg, NJ, USA). CD4 cell count was 
determined by routine flow cytometry using TriTest CD4/CD8 with TruCount Tubes 
(Becton Dickinson Biosciences, San Jose, CA, USA). All laboratory analyses were 
performed at the Department of Clinical Chemistry at Ullevål University Hospital. 
4.1.3 Statistical analyses 
All statistical analyses were worked out in tight collaboration with Prof. Leiv Sandvik, Oslo 
University. The software package SPSS
®
 (SPSS Inc, version 14.0, Chicago, Ill, USA) was 
used to perform the statistical analyses. Differences/associations with a p-value <0.05 were 
considered statistically significant in all papers. Data were first tested for normality of 
distribution. Data are expressed either as the mean ± standard deviation (SD), as a number 
and percentage, or as the median with the interquartile range for skewed data. While for the 
comparison of two continuous variables a Student’s t-test was used, the Mann–Whitney U 
test was chosen for skewed data. Dichotomous variables were compared with the Fisher’s 
exact test. Logistic regression analyses was used to describe the relationship of a 
dichotomous dependent variable and related independent variables, using a backward 
stepwise procedure, with P-to-enter < 0.1 and P-to-remove > 0.1. Odds ratio (OR) was 
calculated by logistic regression analysis or cross tables. Linear regression analysis (paper 
II) was used to assess associations between continuous dependent variables and selected 
independent variables, expressed as the unstandardized coefficient (B) and standard error 
(SE). Independent variables correlating with r > 0.7 were not included simultaneously in a 
regression analysis. For comparison between multiple groups, one-way analysis of variance 
and Pearson’s 
2 
linear-by-linear association to test categorical variables was used.  
 41 
%	&		!			
5.1 Paper I 
Microalbuminuria associated with indicators of inflammatory activity in an HIV-
positive population. 
Nephrology Dialysis Transplantation. 2008;23:3130-3137. 
 
The aim of this study was to identify the prevalence of microalbuminuria in a HIV-cohort, 
furthermore to compare the findings in the Caucasian HIV-infected individuals to a matched 
general population. 
The HIV study cohort consisted of 495 nonhypertensive and nondiabetic patients. 
Microalbuminuria was determined on the basis of three urine samples. 
The prevalence of microalbuminuria was 8.7% in the HIV-infected cohort, which is 3–5 
times higher than in the general population. Systolic blood pressure, serum beta 2-
microglobulin and duration of HIV infection emerged as independent predictors of 
microalbuminuria. 
It was concluded that microalbuminuria was markedly increased in HIV-infected 
individuals compared to the general population, due to hemodynamic effects and possibly to 
increased inflammatory activity. 
5.2 Paper II 
Hypertension in an Urban HIV-Positive Population Compared with the General 
Population: Influence of Combination Antiretroviral Therapy. 
Journal of Hypertension. 2008;26:2126-2133. 
 
The aim of this study was to identify the prevalence of hypertension in an entire HIV-cohort 
and compare the findings in the Caucasian HIV-infected individuals to an age, gender, and 
body mass index matched general population. 
The HIV study cohort consisted of 542 unselected individuals. Hypertension, defined as 
140/90 mmHg, was based three measurements taken in duplicate under standardized 
procedures. 
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The prevalence of HT among the Caucasian HIV-infected subjects was 36.5%, which was 
not significantly different from that of the general population although the diastolic BP was 
higher in HIV-cohort. The highest prevalence of HT was found in those who were treated 
by cART for more than five years, while the lowest was found in those treated <2 years and 
not in cART naïve individuals. However, beside traditional risk factors, cART duration 
emerged as an independent predictor for hypertension.  
It was concluded that the prevalence of hypertension in Caucasian HIV-infected individuals 
did not differ from that of the general population. However, cART seemed to induce an 
inscrutable time dependent difference on the blood pressure. 
5.3 Paper III 
Association between HIV infection and attenuated diurnal blood pressure rhythm in 
untreated hypertensive individuals 
HIV Medicine. 2009;10:44-52. 
 
The aim of the study was to investigate the diurnal blood pressure rhythm in newly 
diagnosed hypertensive HIV-infected individuals and compare them to HIV-uninfected 
controls. 
Ambulatory blood pressure was measured over 24 h in 77 unselected newly diagnosed 
hypertensive individuals from the study cohort. 
A blunted nocturnal blood pressure fall was more frequent in the HIV-infected individuals 
compared to the hypertensive individuals without HIV infection (60% vs. 33%, 
respectively; P = 0.001). This finding was dependent on the HIV status, but seemed 
independent of the exposure to cART. 
It was concluded that the prevalence of a nondipping BP pattern in HIV-infected subjects 
with hypertension was significantly higher than in hypertensive control subjects.
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6.1 Discussion of the results 
The main findings of this thesis are the lucidly increased prevalence of microalbuminuria in 
HIV-infected individuals, which in the Caucasian fraction was 2-4.7 times higher compared 
to the general population, and secondly the pioneering finding of the attenuated nocturnal 
ambulatory blood pressure rhythm in the newly diagnosed hypertensive individuals. 
Thirdly, we observed an interesting ‘oscillating’ prevalence of hypertension in the MAHO 
cohort with reduced prevalence in the initial phase after initiating cART compared to naïve 
and cART exposure beyond two years. 
6.1.1 Prevalence 
Compared to the general population the prevalence of MA was mostly increased in HIV-
infected men <50 years. Supported by the duration of HIV infection and beta 2-
microglobulin as independent predictors for MA, one might speculate that in these young 
individuals the inflammatory component is most pronounced, whereas in the older age 
groups traditional risk factors become more prominent. Even in HIV-positive women <50 
years the prevalence of MA was relatively high compared to uninfected controls (5.8% vs. 
2.4%, P = 0.18), but the group was to small to reach statistical significance. Previously, and 
at the time of planning of our study no data were available. A multicenter study in which the 
prevalence of MA in HIV-infected individuals was investigated, was published while we 
were preparing paper I. That study was in contrast to ours, however, based on a selected 
population of the Fat redistribution and metabolism (FRAM) study with significant 
lipodystrophy as an entry criterion.
84
 Therefore, we do consider that our findings not only 
confirm previous studies, but also are original in an unselected urban HIV cohort compared 
to a highly representative general population. 
Paper II was the first study to investigate the prevalence of HT in an entire HIV cohort and 
compare it with an age, gender and BMI-matched general population. The finding that HT is 
not increased in HIV-infected individuals compared to the general population, is in line with 
the DAD study and others,
93,96,105
 who attribute changes in BP rather to traditional risk 
factors for hypertension than to cART or HIV it self. The prevalence of hypertension (HT) 
in different selected HIV-infected cohorts ranges from 8% to 34%.
93-100
 Thus, our results are 
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in the higher range. Only a few studies have investigated the prevalence of HT
93,94,96,99,100
 
together with blood pressure (BP)
93,96,101
 in HIV-infected populations compared with HIV-
negative controls and have showed diverging results. Unstandardized BP measurements, 
diversity in study populations and/or control groups and lack of adjustment for confounding 
factors may explain the nonuniform results. Another interesting finding of our study, 
especially considering the low number of treated hypertension, is that isolated systolic 
hypertension seems to be the prominent related subgroup of hypertension between naïve and 
cART subjects as well as within the different cART groups based on treatment duration. 
Isolated systolic hypertension is most common in the elderly subjects
134
 and has been shown 
to be more closely correlated to cardiovascular risk than diastolic hypertension.
135
 
Moreover, the prevalence of isolated systolic hypertension in the HIV-infected cohort is 
comparable to that in a 5-15 years older general population.
136
 Thus, it seems that the HIV 
population may develop isolated systolic hypertension earlier than the general population, 
indicating that vascular stiffness may occur at a younger age due to atherosclerosis and 
metabolic aberrations. 
Paper III revealed a very high prevalence of nondipping pattern in the HIV-positive cohort 
compared to the HIV-negative control group. We do not have a reasonable explanation but 
wish to investigate this in the near future. Unfortunately only few cART naïve individuals 
entered the study, but cART did not seem to affect the ABP pattern. A postulated hypothesis 
might be among others, that inflammatory processes could influence the diurnal blood 
pressure rhythm in HIV-infected patients. Van Kanel et al. observed in a group of relatively 
young unmedicated HIV-uninfected individuals that nondipping BP pattern seems to be 
related to inflammatory markers and endothelial dysfunction.
124
 Another attractive 
speculation could be cART-induced processes and even an unknown inherent kidney 
abnormality causing tubular sodium handling, could explain the abnormal circadian 
pattern.
137
 
6.1.2 The impact of traditional risk factors 
In paper I and II the main traditional risk factors for MA and HT, such as age (I and II), BP, 
creatinine, GFR (paper I), male sex, BMI, cholesterol and MA (paper II) were confirmed in 
our study. Others, such as gender, smoking, cholesterol (paper I) and ethnicity (paper I and 
II) did not reach statistical significance. It has to be emphasized that the MAHO cohort is 
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relatively young and too small to reveal the entire ‘picture’ of MA and HT. However, 
despite that, the shared traditional risk factors, with that of the general populations may 
express strength of validity in our cohort. 
In paper III we did not find significant difference in MA between dipping and nondipping 
pattern (9.7% vs. 22.7%; P = 0.14), as it would have been expected, but this could be due to 
low statistical power. 
6.1.3 The impact of HIV duration/inflammation 
HIV duration and beta 2-microglobulin, a marker of immunoactivity emerged as 
independent predictors for urinary albumin excretion, suggesting an inflammatory 
component in the development of MA. Only Luke et al. have observed in a small selected 
cohort, higher levels of TNF in patients with MA before the era of cART.
82
 To date, no 
study has investigated more specific biomarkers for endothelial dysfunction (vWf, sVCAM-
1, sICAM-1, sE-selectin) or inflammation (hs-CRP, IL-6, fibrinogen) in HIV-infected 
individuals with and without MA. This would require fasting blood samples taken and 
stored under standardized procedures, which we unfortunately did not do for the present 
study. 
There seems to be a gender difference in the predictors of MA. HIV duration was a 
predictor for MA in men, but not in women. In contrast, beta 2-microglobulin was a 
predictor for MA in women, but not in men (paper I). This could reflect a beneficial effect 
of female sex hormones on inflammation and endothelial dysfunction, and has been 
suggested to be the explanation for less cardiovascular disease in premenopausal women 
compared to men.
138,139
 
HIV infection per se was the only independent predictor of attenuated BP rhythm among 
these hypertensive individuals. The explanation remains obscure, but inflammatory 
processes have to be considered and our findings need to be confirmed not only in other 
HIV-infected cohorts, but also in normotensive individuals with HIV infection.  
We did not identify an association between CD4 or viral load and the primary outcome, i.e. 
MA, HT or dipping status. Decreasing CD4 cell count, and increasing viral load are known 
to correlate with disease progression and the duration of HIV infection. After the 
introduction of cART this continuum has been interrupted and even reversed. The immune 
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capacity in our cohort was well maintained as 85% had a CD4 cell count above 0.2x10
9
 
cells/l and close to 50% had HIV RNA below 400 copies/ml. Furthermore, important 
traditional risk factors for MA and HT are influenced by the adverse events of the 
antiretroviral therapy. In a population where more than half of the patient are using cART 
an analysis would therefore be highly confounded. However, even in cART naïve patients, 
no association could be found between CD4 or HIV RNA and MA or HT. Crane et al. found 
increased SBP or new diagnosis of HT in HIV-infected individuals with CD4 cell count 
below 200/mm
3
 at treatment start with cART, after a mean cART exposure of 13.5 
months.
104
 Also increased odds of chronic renal failure has been observed in HIV-infected 
individuals with lower nadir CD4 cell count.
35
 Therefore, it might be interesting to 
investigate the level of CD4 cell count at treatment start in HIV-infected individuals with 
MA or HT compared to those without in our cohort.  
6.1.4 The impact of cART and its duration 
The majority of individuals in our cohort received cART, and more than two third of them 
received a PI containing regime. In paper I and III, cART had no influence on MA or 
nondipping pattern, while cART duration was predictive for HT (paper II) in HIV-infected 
individuals. These findings must be interpreted with caution as the matched cohort became 
rather small to study especially low prevalence’s such as MA (paper I). Moreover, HT 
varied substantially on the basis of cART duration. There was no difference in the 
prevalence of HT between cART naïve and cART individuals (paper II), but the number of 
cART naïve individuals in paper III was exceedingly low. Furthermore, in paper II, one 
might speculate that BP may decrease promptly after the initiation of cART, possibly due to 
an improved inflammatory state.  However, in the long run, the enhancing effects of the 
chronic HIV inflammation on BP alongside with metabolic side effects induced by cART 
may prevail.
105
 Anyways, the impact of cART adverse events will remain a highly 
controversial topic. We do believe, that the diverging results of previous studies on HT and 
even CVD in HIV cohorts might be due to the difficult interpretation of different cART 
regimes, as therapy frequently are altered in patients due to availability of newer drugs, 
adverse events or failure of the treatment. Thus, we have not specified cART regimes in our 
study participants. Finally, it is even plausible that cART might have a positive impact on 
MA as it has on a deteriorated renal function
43
 and urinary albumin excretion in women.
140
 
This has to be elucidated in more detail in future prospective studies. 
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6.2 Methodological issues 
Even though the MAHO-study was designed and conducted with the aim of reducing 
random and systematic errors the findings may have an alternative explanation.  
6.2.1 Study sample 
The role of chance may always affect the observed results, when we apply them from a 
sample to the entire population. At study start the HIV-cohort of Oslo consisted, based on 
estimations from the Norwegian Surveillance System for Communicable Diseases of 
approximately 800 individuals. Of those 700 followed-up at the outpatient clinic of 
Infectious Diseases, Ullevål University Hospital, 597 were enrolled. Although, the MAHO-
study cohort, with approximately 75% of the possible participants, can be considered as 
highly representative of an unselected urban HIV population in a developed environment 
with almost unlimited free access to health care, one might expect minimal sampling errors, 
i.e. selection bias in the study subjects. Furthermore, this Norwegian cohort has from a 
European perspective a relatively low share of drug abusers, which is reflected by the low 
prevalence of hepatitis C co-infection (9.2%). The majority of newly diagnosed HIV cases 
are either imported from high-endemic countries or men having sex with men. 
In paper I, diabetic and patients using antihypertensive treatment were excluded. We did so 
to minimize the effect of traditional risk factors of MA. Furthermore in the comparison to 
the general population, which is ethnically homogenous, with only 3% of non-Caucasian 
origin, non-Caucasian HIV-positive individuals were excluded (paper I and II). 
Nevertheless, ethnicity did neither affect the prevalence of MA nor of HT. The MAHO 
cohort became statistically to weak when reduced to subgroups by matching it to the general 
population. Also in the future our cohort will probably only produce reasonable sized 
subgroups >35 years for cART individuals and between 20 and 30 years for naïve 
individuals. Even more difficult will it be for the female gender.  
Only slightly more than 50% of the newly diagnosed hypertensive HIV-infected individuals 
responded to the ABP monitoring invitation (paper III). This was mainly due the necessity 
to start promptly antihypertensive treatment after the diagnosis of HT. Thus, there was a 
difference in casual diastolic blood pressure of approximately 3 mmHg between those 
included in the ABP study and those who did not attend. We may only speculate what 
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implications this could have. However, it may indicate that we actually underestimate the 
true occurrence of blunted diurnal blood pressure rhythm, as one may expect on abnormal 
blood pressure rhythm with lower casual blood pressure levels. Furthermore, we had a 
control group of untreated hypertensive individuals, which unfortunately differed 
substantially in casual blood pressure. However, the percentage of dipping pattern in the 
HIV-negative group is comparable to other observations.
141
 
6.2.2 Limitations of the study 
In the collection of the data several physicians and nurses have been involved, this could 
potentially affect the data quality. The questionnaire regarding medical history, 
hypertension, diabetes, smoking, use of NSAID’s, drug abuse and cancer was completed by 
the physician, based on information from the patients. Thus, information might be under- 
(e.g. smoking, drug abuse, presence of hypertension or urinary tract infection) or 
overestimated by the participants. In certain cases of doubt the medical record gave 
additional supportive information about the patients history. 
Usually, possible misclassification of for example MA would be expected to occur 
randomly and dilute associations. However, this would be a problem if the misclassification 
was differential or non-random. 
MA was repeatedly collected and analysed under standardized procedures, ideally taken as 
midstream morning sample. While the first urine sample was taken at the same time with 
the clinical visit between 9 am and 3.30 pm, the second and third were supposed to be taken 
at home as midstream morning sample. If forgotten, the sample was collected at the 
outpatient clinic at the time of the visit. The day-to-day variation in MA might have 
influenced the results. Likewise, the blood samples were supposed to be taken after an 
overnight fasting, between 8 and 11 am, however, we do not know that all patients followed 
the recommendation about fasting.  None of the main blood parameters (CD4 cells, HIV-
RNA, beta 2-microglobulin, creatinine) were dependent on fasting samples. BP 
measurement procedures were highly standardized, but time and interval differed according 
to the clinical visit. 
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The intervals between the three clinical visits varied between 1 to 34 months. Ideally the 
patients should attend clinical examination every 3
rd
 month. Despite the variability in the 
time frame, only 25 individuals started cART between the first and third visit.  
HIV duration was calculated on the basis of the first positive HIV test, and the correctness 
of this could be discussed. However, it may be difficult to ascertain the correct point of time 
at which the individuals became HIV-positive. This is especially the case for some of the 
HIV-infected immigrants, who had frequently more advanced disease before they actually 
underwent HIV testing.  
In addition, we have ‘thrown a line’ between HIV infection/duration and inflammatory 
activity as a cause for the high prevalence of microalbuminuria and the abnormal blood 
pressure pattern, which remains speculative. Thus, investigations of inflammatory markers 
are dearly needed. This will require fasting blood samples taken and stored under 
standardized procedures, which we unfortunately did not do in the first MAHO study. 
Because direct GFR measurements are expensive and inconvenient, estimated GFR was 
calculated by the MDRD equation. This is in line with the recommendations by the National 
Kidney Foundation
142
 and has even been evaluated in our population-based control group.
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However, the accuracy of the MDRD equation to estimate GFR might have some 
limitations, due to age and degree of renal disease and underestimates GFR in populations 
characterized by normal serum creatinine levels.
144
 Nevertheless, MDRD equation has not 
been evaluated in HIV-infected individuals.  
6.2.3 Representativeness and generalizability 
An important question is whether the conclusions based on the MAHO cohort can be 
considered valid for the HIV-infected patients in Oslo. The MAHO-study enrolled 
approximately 75% of the HIV-infected individuals in Oslo, and of those >90% completed 
the study with three clinical visits. Non-participants have not been registered and analysed, 
but one might speculate if several immigrants with limited language knowledge and 
ongoing drug abusers have not been included in the study. However, neither ethnicity nor 
drug abuse did influence our findings. Although the MAHO cohort has a statistically 
satisfactory size as a whole, when splitting in gender and age decades for the comparison 
with the general population, certain groups became too small and lack statistical power 
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especially for analyses of low prevalence’s such as MA. Furthermore, to increase the 
statistical power of our finding, we categorized BP to HT, ACR to MA and nocturnal BP 
fall to nondipping status, while the linear analysis might identify a more accurate picture of 
this young cohort.   
We used the HUNT-2 data from the years 95-97 as control group (paper I and II). There 
might have been changes in treatment and follow-up of diabetic and/or hypertensive patients 
with MA, which could have affected the presence of MA, but as these patient groups were 
excluded for statistical analyses, treatment changes over time should not affect the 
prevalence of MA in the general population in paper I. It is furthermore uncertain, whether 
the prevalence of HT in the HUNT-cohort has changed in the last decade. Both the 
Norwegian HUNT
145
 and Tromsø
146
 cohorts observed an increase linked to BMI over the 
preceding decade.  The definition of HT and MA were identical in our study and the HUNT 
study. However, the sampling procedures, laboratory facilities, BP device and the number of 
BP measurements differed substantially between the two studies. 
Several variables were potential confounders, and not all could be included and adjusted for 
in the analyses. The choice of variables treated as confounders in the analyses were based 
on our knowledge of risk factors associated with MA or HT and were addressed in the 
questionnaire. Even so, alcohol, physical activity, dietary nutrient intake and other 
medications do all constitute potential independent, unmeasured factors that might be 
associated with exposure. There were no exact data on medications, unless NSAID’s, 
antihypertensive medications and cART. Some study support the hypothesis that both 
aspirin and statins have anti-inflammatory effects and decrease CRP.
147,148
 Neither the 
impact of lipodystrophy, nor the sub-group lipoatrophy were identified and analyzed in our 
study. While, it is reasonably to assume that like for cART the traditional risk factors for HT 
account for most of the burden in lipodystrophic individuals, lipoatrophy seems more likely 
to influence BP independently in HIV-infected individuals. It is uncertain how this might 
have inflicted our results and leads us to the lack in our study of more specified analyses of 
cART. As discussed previously, we do believe that the interpretation of the influence of 
different cART regimes in HIV cohorts might be difficult, as therapy frequently are altered 
due to availability of newer drugs, adverse events or failure of the treatment. Furthermore, 
cART subgroups would have reduced the statistical power. However, we analysed PI in 
paper II and could not identify any association to HT or difference in the prevalence of HT 
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between PI and non PI containing cART regimes. The study was performed in an urban 
setting and might hence only generalize to comparable locations. However, despite the high 
attendance, the MAHO-study cohort has a rather low external validity for a general urban 
HIV-populations. While age, gender, HIV duration and naïve/cART distribution might be 
fairly similar to other city cohorts in the industrialised world; this does not apply for 
ethnicity, transmission mode and socioeconomic status. However, it seems rather futile to 
reach this goal since the disease is partly dependent on cultural behaviour and there will 
always exist substantial differences between international cohorts. Furthermore, comparison 
of the prevalence of MA and HT were limited to the Caucasian population, as the HUNT-2 
control group has a low percentage of non-Caucasian. The generalisation might therefore be 
limited at the most to Caucasian HIV-infected individuals in urban areas. 
6.3 Implications 
In terms of attention towards BP measurement, the MAHO-study has already had an impact 
on the daily clinical care of the patients in the ward and at the outpatient clinic of the 
infectious disease department. Clinicians have also become increasingly aware of the 
importance of BP follow-up and the usefulness of ABP monitoring.  
There is clearly a need for further large, prospective studies on MA, HT and impact of 
intervention. Furthermore, the threshold of BP intervention and specific drug therapy has to 
be identified, if it should differ from the general population. The findings with regard to 
ABP should be confirmed in larger studies, also in normotensive HIV-infected individuals. 
The relationship between diurnal blood pressure rhythm in relation to cardiovascular and 
renal diseases in both naïve and cART cohorts should be explored. Even more it is 
imperative to carry out some of these studies also in HIV-infected individuals of African 
and Asian origin. 
The up to four-fold increase in MA might have predictive value for cardiovascular and renal 
diseases as demonstrated for the general population. Studies, in large international cohorts 
need to be undertaken to prove this theory. The detection of MA might identify a subgroup 
of patients with several modifiable risk factors for CVD, like overweight, hyperlipidemia, 
hypertension, smoking and glucose intolerance. Correction of these abnormalities by 
lifestyle and/or pharmacological therapy might reduce the incidence of cardiovascular 
events, but needs to be further explored. Chronic kidney disease is today defined according 
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to the National Kidney Foundation and Infectious Disease Society of American guidelines 
as a GFR< 60 ml/min/1.73 m
2
 and/or the presence of proteinuria, confirmed on two or more 
measurements separated by at least 3 months.
32
 However, the use of quantitative test, i.e. 
ACR is likely to provide a more accurate assessment and allow for identification of renal 
disease in more patients with HIV infection.
149
 Recognition of early, subclinical kidney 
disease may allow the initiation of cART and other interventions, such as ACE-inhibitors or 
angiotensin receptor antagonists,
150
 which might prevent or delay progression to ESRD. A 
recent biopsy study demonstrated early HIVAN in six South African patients with MA, who 
would not have undergone kidney biopsy as part of standard clinical care. The potential of 
MA in detecting kidney disease was confirmed by an autopsy study from New York, who 
demonstrated a high prevalence of chronic kidney disease in a cohort of cART-exposed 
individuals and presumed that several individuals could have been identified by pre-mortem 
MA testing.
88
 Nonetheless, it remains uncertain if screening for MA can be recommended to 
‘healthy’ HIV-infected individuals in order to detect subclinical CV and CKD. 
In the era of cART, HT constitutes, alongside with increased cholesterol and BMI a major 
modifiable risk factor for cardiovascular and renal diseases. If cART it self or cumulative 
exposure have a deleterious effect on BP remains uncertain and will be difficult to identify 
as new drugs and even groups will probably emerge on the scenery. However, as HIV-
patients age they become hypertensive whether using cART or not, and should be followed 
up with at least the same attention as the general population, including life style 
modifications. Unfavourable lipid effects of thiazide diuretics must be ‘kept in mind’. As in 
type II diabetes, the best choice of treatment in cART patients with MA associated with HT 
might be an ACE inhibitor or angiotensin receptor antagonists, but no randomised trials 
comparing different antihypertensive drugs in HIV-infected individuals are published. 
The clinical indications in the general or hypertensive population of ABP monitoring remain 
arguable and limited to institutions where facilities are available. However, accumulated 
evidence now points to greater prognostic significance in determining risk for hypertensive 
end-organ damage compared with office BP measurements. This is especially true for 
nondippers. Thus, one might speculate if the identification and treatment of attenuated blood 
pressure in hypertensive HIV-infected individuals could decrease the incidence of CVD. 
This hypothesis may be difficult to prove, as it would require large long-term studies. 
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6.4 Future research 
The MAHO-study was designed as a prospective investigation of MA and BP in the era of 
cART. The second part of the MAHO-study has been started in 2007. That part will give us 
the possibility to explore the changes in urinary albumin excretion, GFR and BP in a HIV-
infected cohort over time and detect possible relationships to traditional risk factors and 
HIV-related factors. Furthermore, we will focus on fasting blood samples for certain 
hormone analyses and their relationship to MA, HT and cART. In addition, we could 
explore the different main components of cART in association to MA and nondipping BP 
pattern. Moreover, it is necessary to confirm our ABP findings in normotensive HIV-
infected patients and detect potential cardiac end organ damages. 
Several questions arise regarding inflammatory implications of HIV in the development of 
MA and attenuated diurnal BP rhythm. Therefore, we will continue our investigations and 
improve laboratory procedures in selected subgroups of both cART naïve and cART 
individuals in order to study inflammatory processes. Many inflammatory markers are 
conceivable to have impact on atherogenesis and in collaboration with the Department of 
Infectious Disease, Rikshospitalet, Oslo University Hospital, a paper was recently accepted, 
were we observed a positive associations between osteoprotegrin, soluble TNF-receptor 
type 1 and microalbuminuria in naïve patients.   
Since our findings are limited to a primarily Caucasian HIV-infected, our model might be 
repeated in an African setting. This would be especially interesting regarding the predictive 
value of MA for the development of chronic kidney disease in the continent where the HIV 
epidemic has by far the most deleterious consequences.
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The prevalence of MA was 2-4.7 times higher in Caucasian HIV-infected individuals 
compared to the general population. As beta 2-microglobulin and HIV duration were, beside 
hemodynamic effects independent predictors of MA, one might speculate the implication of 
inflammatory activity. Notwithstanding, MA represents a risk factor for CVD and CKD in 
the general population and might even reflect some of the burden among HIV-infected 
individuals. 
The prevalence of HT in HIV-infected was similar compared with an age-, gender-, race- 
and BMI-matched general population. It remains uncertain what deleterious effect might be 
exhibited by and cART itself or its adverse events. Nevertheless, HT constitutes the most 
important risk factor for CVD in the general population and it is therefore mandatory to 
address it closely in HIV-infected individuals. 
Hypertensive HIV-infected individuals were clearly more likely exhibiting a blunted fall in 
nocturnal BP, compared to hypertensive HIV-uninfected individuals. It might be speculated 
that HT in HIV-infected individuals is more aggressive, and a putative cause of the 
increasing CVD among HIV-infected cohorts. 
The reasons and consequences of the increased prevalence of MA, the predictive value of 
cART for HT and the blunted nocturnal BP fall in HIV-infected individuals remain 
uncertain. Beside traditional risk factors we do suspect an inflammatory component. 
However, with regard to the rising number of HIV-infected individuals and their known 
increased risk of CVD and CKD, further investigations seem indispensable.
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